Skip to main content
Sarah Nikiforow, MD, Oncology, Boston, MA

SarahNikiforowMD

Oncology • Boston, MA

Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Nikiforow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Nikiforow's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Dana Farber Cancer Center - Smith 353
    Boston, MA 02215
    Phone+1 617-632-3779
    Fax+1 617-632-5822

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 2005 - 2008
  • Yale School of Medicine
    Yale School of MedicineClass of 2005

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2010 - 2024
  • CT State Medical License
    CT State Medical License 2008 - 2010
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-cell Therapy  
    Sarah Nikiforow, Caron Jacobson, JAMA Neurology

Abstracts/Posters

  • A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
    Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
    Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
    Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Press Mentions

  • Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers
    Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck CancersFebruary 11th, 2021
  • Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers
    Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
  • The Fantastic Voyage of a Bag of Cells Shipped West to Be Trained in the Art of Killing Cancer
    The Fantastic Voyage of a Bag of Cells Shipped West to Be Trained in the Art of Killing CancerOctober 27th, 2017

Dr. Sarah Nikiforow, Dr. Sarah Nikiforow, MD, Dr. S Nikiforow